Ross Nesbit, MD
Nephrology · Knoxville, TNNPI 1386870475
Payments from drug & device makers
Across 1,093 payments — averaging $413.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$131K
- Vifor Pharma, Inc.$112K
- Bayer$101K
- Calliditas Therapeutics US Inc.$59K
- Akebia Therapeutics Inc$22K
- Aurinia Pharma U.S., Inc.$18K
- plus $10K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 258 | $130,600 |
| Vifor Pharma, Inc. | 204 | $111,627 |
| Bayer | 142 | $101,485 |
| Calliditas Therapeutics US Inc. | 76 | $58,527 |
| Akebia Therapeutics Inc | 56 | $22,407 |
| Aurinia Pharma U.S., Inc. | 35 | $17,986 |
| Amgen(2 entities) | 89 | $1,710 |
| Johnson & Johnson | 2 | $1,315 |
| Scpharmaceuticals Inc. | 2 | $1,217 |
| Cipla USA Inc. | 4 | $1,000 |
| Mallinckrodt Hospital Products Inc. | 39 | $774 |
| Travere Therapeutics, Inc. | 28 | $660 |
| Otsuka America Pharmaceutical, Inc. | 33 | $623 |
| Fresenius USA Marketing, Inc. | 27 | $453 |
| Mallinckrodt Enterprises LLC | 10 | $272 |
| Novartis | 14 | $270 |
| Daiichi Sankyo Inc. | 11 | $257 |
| OPKO Pharmaceuticals, LLC | 16 | $227 |
| Sanofi | 7 | $180 |
| GSK | 7 | $125 |
| Shire North American Group Inc | 7 | $113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $66 |
| Alnylam Pharmaceuticals Inc. | 3 | $62 |
| ANI Pharmaceuticals, Inc. | 3 | $61 |
| Lilly USA, LLC | 3 | $50 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| Baxter Healthcare | 2 | $45 |
| Kyowa Kirin, Inc. | 2 | $36 |
| Ardelyx, Inc. | 2 | $33 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
How this compares
$452,285 in reported general payments places this provider in the 95th percentile of 229 nephrology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Knoxville
- Kendra HendonKnoxville$1.1M
- Gerald BorrelliKnoxville$190K
- Denise RiversKnoxville$154K
- Urath SureshKnoxville$109K
- Jimmy GentryKnoxville$38K
- Erik WendlandKnoxville$34K
- Ritu KhannaKnoxville$12K
- Claude GalphinChattanooga$2M
- Wael HusseinMemphis$912K
- Anna BurgnerNashville$788K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.